FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051091083> ?p ?o ?g. }

• W2051091083 endingPage "457" @default.
• W2051091083 startingPage "443" @default.
• W2051091083 abstract "It is unknown if the antiproteinuric effect of angiotensin-converting enzyme (ACE) inhibitors reflects attenuation in the rate of progression of diabetic nephropathy. We report the results of a randomized, double-blind clinical trial designed to evaluate the longitudinal (18-month) effect of the ACE inhibitor, enalapril (5 to 40 mg/d), versus a placebo on 24-hour urinary protein excretion and on the rate of progression of renal disease in 33 patients with clinical diabetic nephropathy. Systemic blood pressure was controlled throughout the trial with conventional antihypertensive drugs. Glomerular filtration rate (GFR), determined by Tc99mDTPA renal clearance, and urinary protein excretion were monitored at 3-month intervals. Enalapril, in contrast to placebo therapy, was associated with an initial (40%) and sustained (33%) decrease in urinary protein excretion. Patients randomized to both enalapril or placebo experienced mean decreases in GFR, from 1.01 mL/s/1.73 m2 (61 mL/min/1.73 m2) to 0.85 mL/s/1.73 m2 (51 mL/min/1.73 m2), and from 1.06 mL/s/1.73 m2 (64 mL/min/1.73 m2) to 0.97 mL/s/1.73 m2 (58 mL/min/1.73 m2), respectively. Eleven of 18 patients (61 %) randomized to enalapril, and 10 of 15 (66%) patients randomized to placebo, had a decrease in GFR; their rates of progression were −1.18 mL/min/1.73 m2/mo and −1.00 mL/min/1.73 m2/mo, respectively. In the absence of changes in blood pressure, the addition of an ACE inhibitor to patients with clinical diabetic nephropathy could not be shown to confer a unique renal protective effect. A prolonged decrease in 24-hour protein excretion could not be shown to predict attenuation in the progression of established clinical diabetic nephropathy. It is unknown if the antiproteinuric effect of angiotensin-converting enzyme (ACE) inhibitors reflects attenuation in the rate of progression of diabetic nephropathy. We report the results of a randomized, double-blind clinical trial designed to evaluate the longitudinal (18-month) effect of the ACE inhibitor, enalapril (5 to 40 mg/d), versus a placebo on 24-hour urinary protein excretion and on the rate of progression of renal disease in 33 patients with clinical diabetic nephropathy. Systemic blood pressure was controlled throughout the trial with conventional antihypertensive drugs. Glomerular filtration rate (GFR), determined by Tc99mDTPA renal clearance, and urinary protein excretion were monitored at 3-month intervals. Enalapril, in contrast to placebo therapy, was associated with an initial (40%) and sustained (33%) decrease in urinary protein excretion. Patients randomized to both enalapril or placebo experienced mean decreases in GFR, from 1.01 mL/s/1.73 m2 (61 mL/min/1.73 m2) to 0.85 mL/s/1.73 m2 (51 mL/min/1.73 m2), and from 1.06 mL/s/1.73 m2 (64 mL/min/1.73 m2) to 0.97 mL/s/1.73 m2 (58 mL/min/1.73 m2), respectively. Eleven of 18 patients (61 %) randomized to enalapril, and 10 of 15 (66%) patients randomized to placebo, had a decrease in GFR; their rates of progression were −1.18 mL/min/1.73 m2/mo and −1.00 mL/min/1.73 m2/mo, respectively. In the absence of changes in blood pressure, the addition of an ACE inhibitor to patients with clinical diabetic nephropathy could not be shown to confer a unique renal protective effect. A prolonged decrease in 24-hour protein excretion could not be shown to predict attenuation in the progression of established clinical diabetic nephropathy." @default.
• W2051091083 created "2016-06-24" @default.
• W2051091083 creator A5033895828 @default.
• W2051091083 creator A5038552789 @default.
• W2051091083 creator A5042881759 @default.
• W2051091083 creator A5065619321 @default.
• W2051091083 creator A5070280493 @default.
• W2051091083 creator A5075585200 @default.
• W2051091083 creator A5083257409 @default.
• W2051091083 date "1992-11-01" @default.
• W2051091083 modified "2023-10-14" @default.
• W2051091083 title "A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Enalapril in Patients With Clinical Diabetic Nephropathy" @default.
• W2051091083 cites W1964377393 @default.
• W2051091083 cites W1965762279 @default.
• W2051091083 cites W1979489935 @default.
• W2051091083 cites W1982291941 @default.
• W2051091083 cites W1983790228 @default.
• W2051091083 cites W1985779699 @default.
• W2051091083 cites W1994055699 @default.
• W2051091083 cites W1996485736 @default.
• W2051091083 cites W1996992946 @default.
• W2051091083 cites W2001049748 @default.
• W2051091083 cites W2001380437 @default.
• W2051091083 cites W2021295171 @default.
• W2051091083 cites W2033503356 @default.
• W2051091083 cites W2036789134 @default.
• W2051091083 cites W2039871464 @default.
• W2051091083 cites W2039877022 @default.
• W2051091083 cites W2044276013 @default.
• W2051091083 cites W2044731824 @default.
• W2051091083 cites W2045261889 @default.
• W2051091083 cites W2047741519 @default.
• W2051091083 cites W2050789305 @default.
• W2051091083 cites W2052608990 @default.
• W2051091083 cites W2059571085 @default.
• W2051091083 cites W2070360227 @default.
• W2051091083 cites W2074643443 @default.
• W2051091083 cites W2075577088 @default.
• W2051091083 cites W2076008026 @default.
• W2051091083 cites W2082246284 @default.
• W2051091083 cites W2316075782 @default.
• W2051091083 cites W4234761423 @default.
• W2051091083 cites W4293247451 @default.
• W2051091083 doi "https://doi.org/10.1016/s0272-6386(12)70256-1" @default.
• W2051091083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1442757" @default.
• W2051091083 hasPublicationYear "1992" @default.
• W2051091083 type Work @default.
• W2051091083 sameAs 2051091083 @default.
• W2051091083 citedByCount "69" @default.
• W2051091083 countsByYear W20510910832013 @default.
• W2051091083 countsByYear W20510910832014 @default.
• W2051091083 countsByYear W20510910832015 @default.
• W2051091083 countsByYear W20510910832016 @default.
• W2051091083 countsByYear W20510910832018 @default.
• W2051091083 countsByYear W20510910832020 @default.
• W2051091083 countsByYear W20510910832021 @default.
• W2051091083 countsByYear W20510910832022 @default.
• W2051091083 crossrefType "journal-article" @default.
• W2051091083 hasAuthorship W2051091083A5033895828 @default.
• W2051091083 hasAuthorship W2051091083A5038552789 @default.
• W2051091083 hasAuthorship W2051091083A5042881759 @default.
• W2051091083 hasAuthorship W2051091083A5065619321 @default.
• W2051091083 hasAuthorship W2051091083A5070280493 @default.
• W2051091083 hasAuthorship W2051091083A5075585200 @default.
• W2051091083 hasAuthorship W2051091083A5083257409 @default.
• W2051091083 hasConcept C10146269 @default.
• W2051091083 hasConcept C126322002 @default.
• W2051091083 hasConcept C126894567 @default.
• W2051091083 hasConcept C134018914 @default.
• W2051091083 hasConcept C142724271 @default.
• W2051091083 hasConcept C159641895 @default.
• W2051091083 hasConcept C204787440 @default.
• W2051091083 hasConcept C27016395 @default.
• W2051091083 hasConcept C27081682 @default.
• W2051091083 hasConcept C2775940317 @default.
• W2051091083 hasConcept C2778653478 @default.
• W2051091083 hasConcept C2779611605 @default.
• W2051091083 hasConcept C2779922275 @default.
• W2051091083 hasConcept C2781184683 @default.
• W2051091083 hasConcept C555293320 @default.
• W2051091083 hasConcept C71924100 @default.
• W2051091083 hasConcept C77411442 @default.
• W2051091083 hasConcept C84393581 @default.
• W2051091083 hasConcept C90924648 @default.
• W2051091083 hasConceptScore W2051091083C10146269 @default.
• W2051091083 hasConceptScore W2051091083C126322002 @default.
• W2051091083 hasConceptScore W2051091083C126894567 @default.
• W2051091083 hasConceptScore W2051091083C134018914 @default.
• W2051091083 hasConceptScore W2051091083C142724271 @default.
• W2051091083 hasConceptScore W2051091083C159641895 @default.
• W2051091083 hasConceptScore W2051091083C204787440 @default.
• W2051091083 hasConceptScore W2051091083C27016395 @default.
• W2051091083 hasConceptScore W2051091083C27081682 @default.
• W2051091083 hasConceptScore W2051091083C2775940317 @default.
• W2051091083 hasConceptScore W2051091083C2778653478 @default.
• W2051091083 hasConceptScore W2051091083C2779611605 @default.
• W2051091083 hasConceptScore W2051091083C2779922275 @default.
• W2051091083 hasConceptScore W2051091083C2781184683 @default.

• next